Pemigatinib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), CHUIKYO (Japan) and DMC (Denmark), among others, recommended or restricted pemigatinib, while HAS (France) and NYE METODER (Norway) did not recommend it.
The record spans 4.4 years, opening at AWMSG (Wales) on 5 May 2021 and running to 9 Oct 2025.
CIPM (Spain) changed its position: not recommended on 25 Nov 2021, recommended by 23 Nov 2023, after a resubmission.
No assessment is on file from PBAC (Australia) and PHARMAC (New Zealand), each among the eight highest-volume agencies here.
The file is active: 4 of 14 records date from 2023 or later.
3 distinct indication wordings are recorded for pemigatinib by the agencies that label one in English (AWMSG, NICE and SMC).
AWMSG (Wales) was first to assess pemigatinib, on 5 May 2021; AOTMIT (Poland) did not open a file until 9 Oct 2025 — a wide spread of 4.4 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 6 of 14 dated records fall in 2021 alone.
CIPM (Spain) is the only agency to have returned to pemigatinib, recording 3 separate entries.
pemigatinib has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for pemigatinib reads 6 recommended, 4 not recommended, 3 restricted and 1 deferred to NICE.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HIRA (South Korea) | 9 Jan 2025 | FGFR2 융합 또는 재배열 담관암 | reimbursement appropriate | source |
| TLV (Sweden) | 20 Sep 2024 | Pemazyre ingår i högkostnadsskyddet | general subsidy | source |
| NYE METODER (Norway) | 11 Dec 2022 | Monoterapi til behandling av voksne med lokalt avansert eller metastatisk kolangiokarsinom (gallegangskreft) med fibrobl… | not introduced | source |
| CIPM (Spain) | 3 Mar 2022 | Indicaciones terapéuticas autorizadas: Pemazyre en monoterapia para el tratamiento de adultos con colangiocarcinoma loca… | not financed by the SNS (financed 2023-11) | source |
| DMC (Denmark) | 23 Feb 2022 | Cholangiokarcinom | Anbefalet | source |
9 further decisions for pemigatinib, across 8 agencies, are not shown here. They include the most recent record on file, 9 Oct 2025 from AOTMIT (Poland); its outcome is in the subscriber dataset. They link to 9 further source documents.
Related molecules
- ibrutinib — same ATC class L01E — Antineoplastics
- zanubrutinib — same ATC class L01E — Antineoplastics
- cabozantinib — same ATC class L01E — Antineoplastics
- selpercatinib — same ATC class L01E — Antineoplastics
- acalabrutinib — same ATC class L01E — Antineoplastics
- ribociclib — same ATC class L01E — Antineoplastics
Coverage: 14 decisions for pemigatinib from 12 agencies, 2021 to 2025. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.